Evelo Biosciences, Inc.
EVLODelisted Dec 27, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001694665
Evelo Biosciences, Inc. was delisted on Dec 27, 2023; its insiders filed their last Form 4 on Nov 8, 2023; 29 institutions reported holding it in 13F filings for Q3 2023, worth $52.0M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:58 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 16, 2023 | Mar 24, 2022 | Mar 9, 2021 | Feb 13, 2020 | Feb 14, 2019 |
| Operating expenses | $108.5M | $115.4M | $91.9M | $86.4M | $58.1M |
| Research and development | $78.6M | $83.6M | $69.6M | $63.1M | $39.9M |
| Selling, general and administrative | $29.9M | $31.8M | $22.3M | $23.2M | $18.2M |
| Operating income | -$108.5M | -$115.4M | -$91.9M | -$86.4M | -$58.1M |
| Interest expense | – | – | – | – | $900.0K |
| Income tax | $930.0K | $428.0K | $409.0K | $190.0K | – |
| Net income | -$114.5M | -$122.2M | -$93.7M | -$85.5M | -$56.9M |
| EPS, basic | $-1.31 | $-2.31 | – | – | – |
| EPS, diluted | $-1.31 | $-2.31 | – | – | – |
| Weighted shares, basic | 87.2M | 52.9M | – | – | – |
| Weighted shares, diluted | 87.2M | 52.9M | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 16, 2023 | Mar 24, 2022 | Mar 9, 2021 | Feb 13, 2020 | Feb 14, 2019 |
| Cash and equivalents | $47.9M | $68.4M | $68.9M | $77.8M | $93.1M |
| Total current assets | $51.6M | $71.0M | $71.0M | $81.0M | $151.6M |
| Property, plant and equipment | $4.84M | $6.62M | $7.48M | $8.34M | $6.92M |
| Total assets | $64.4M | $87.9M | $90.6M | $90.9M | $159.9M |
| Accounts payable | $1.76M | $1.60M | $1.44M | $620.0K | $1.52M |
| Total current liabilities | $12.4M | $17.4M | $19.8M | $9.74M | $9.23M |
| Long-term debt | $43.6M | $46.6M | $30.0M | $19.6M | $12.3M |
| Total liabilities | $69.4M | $79.2M | $60.2M | $30.7M | $22.9M |
| Shareholders' equity | -$4.99M | $8.67M | $30.5M | $60.2M | $136.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 16, 2023 | Mar 24, 2022 | Mar 9, 2021 | Feb 13, 2020 | Feb 14, 2019 |
| Operating cash flow | -$101.2M | -$96.7M | -$73.1M | -$72.0M | -$47.3M |
| Capital expenditures | $622.0K | $1.52M | $1.32M | $3.03M | $5.46M |
| Free cash flow | -$101.9M | -$98.2M | -$74.4M | -$75.0M | -$52.7M |
| Stock-based compensation | $15.2M | $15.8M | $8.47M | $8.16M | $6.06M |
| Investing cash flow | -$622.0K | -$1.48M | -$1.31M | $52.0M | -$60.1M |
| Financing cash flow | $81.7M | $97.5M | $65.5M | $4.99M | $162.0M |
| Net change in cash | -$20.7M | -$666.0K | -$8.91M | -$15.0M | $54.6M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 6, 2023 | 18.9M | −82.7% | SEC |
| Aug 10, 2023 | 18.8M | −82.6% | SEC |
| May 8, 2023 | 112.0M | +108.7% | SEC |
| Mar 10, 2023 | 110.9M | +106.8% | SEC |
| Nov 8, 2022 | 109.6M | +105.0% | SEC |
| Aug 8, 2022 | 108.0M | +102.2% | SEC |
| May 9, 2022 | 53.7M | +0.5% | SEC |
| Mar 21, 2022 | 53.6M | +0.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2017, from 13F share counts: 1-for-20 in Q2 2023.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.